OncoMatch/Clinical Trials/NCT04539977
PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer
Is NCT04539977 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including TQB2450 and TQB2450 for small-cell lung cancer.
Treatment: TQB2450 · TQB2450 — This is a non-randomized, open-label, single-center, phase II trial to evaluate the safety and effectiveness of surgery or radiotherapy after PD-L1 inhibitor (TQB2450) and chemotherapy induction therapy followed by maintenance therapy as first-line treatment in patients limited-stage SCLC.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage IV, III, LOCAL ADVANCED
extensive stage or limited stage (local advanced) confirmed by imageological examinations.
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anti-cancer treatment
Participants who have received any systemic anti-cancer treatment for SCLC, including surgical treatment, local radiotherapy, cytotoxic drug treatment, targeted drug treatment and experimental treatment
Cannot have received: Chinese medicine against cancer
Administration of any Chinese medicine against cancer before administration of the drug
Lab requirements
Blood counts
ANC count ≥1.5×10^9/L, platelet count ≥100×10^9/L, hemoglobin ≥90 g/L; INR and PT < 1.5×ULN; APTT ≤1.5×ULN
Kidney function
Liver function
total bilirubin ≤1.5×ULN; ALT/AST ≤2.5×ULN, or ≤5×ULN with liver metastatic tumor
Patients with good function of other main organs (liver, kidney, blood system, etc.): * ANC count ≥1.5×10^9/L, platelet count ≥100×10^9/L，hemoglobin ≥90 g/L; * the international standard ratio of prothrombin time (INR) and prothrombin time (PT) < 1.5 times of upper limit of normal (ULN); * partial thromboplastin time (APTT) ≤1.5×ULN; * total bilirubin ≤1.5×ULN; * alanine aminotransferase (ALT) aspartate aminotransferase (AST) ≤2.5×ULN, or ALT and AST ≤5×ULN in the patients with liver metastatic tumor.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify